AdvaMed, CMS Take Conflicting Views On FDA Lab Test Waiver Requirements
This article was originally published in The Gray Sheet
Executive Summary
FDA will need to consider diverging opinions from outside groups as it develops a policy on the requirements for diagnostic test manufactures seeking permission to market assays to laboratories that are under minimal government oversight